Innovative Alliance in Antibody Therapeutics Development
Orion Corporation and Abilita Therapeutics have announced a strategic collaboration focused on pioneering antibody therapeutics aimed at addressing significant medical challenges, notably in oncology and pain management. This partnership signifies a mutual commitment to reshape therapeutic solutions and enhance patient outcomes.
Exploring New Frontiers in Therapeutics
The joint venture grants Orion exclusive access to Abilita's cutting-edge Enabled Membrane Protein (EMP™) technology, which has been designed to aid in the discovery of novel antibody therapeutics targeting GPCR (G protein-coupled receptors) and ion channels. As both companies combine their unique expertise, they are positioned to unlock new therapeutic avenues for conditions that currently lack effective treatment options.
Structure of the Collaboration
As part of the agreed framework, Orion is entrusted with selecting additional therapeutic targets while managing the funding for co-research efforts. Orion will take charge of developing and commercializing up to three novel antibodies stemming from the collaboration, showcasing their commitment to bring effective treatments to market swiftly.
Benefits for Abilita Therapeutics
Abilita stands to benefit significantly from this collaboration as they will receive upfront and milestone payments based on development phases and sales outcomes. Furthermore, they will earn royalties from the successful commercialization of the developed antibody programs. This approach not only incentivizes Abilita but also ensures continued innovation within their therapeutic pipeline.
Leveraging Advanced Technologies for Breakthrough Solutions
Both Orion and Abilita are excited to merge their strengths in their respective fields. Orion aims to enhance patient care with innovative research and development, while Abilita focuses on refining their EMP™ platform—recognized as a leader in directed evolution technology—designed to unlock challenging therapeutic targets. This synergy is expected to speed up the transition of these promising treatments into clinical settings, ultimately benefiting patients in need of effective therapies.
Orion Corporation: A Legacy of Pharmaceutical Innovation
Orion Corporation has built its reputation over more than a century as a leading Finnish pharmaceutical company dedicated to improving well-being. Their extensive portfolio of human and veterinary pharmaceuticals includes both proprietary and generic medications, with a focus on oncology and pain therapy. Recent figures indicate that Orion's net sales reached an impressive EUR 1,190 million, reflecting the company’s successful impact on the pharmaceutical landscape.
Commitment to Research and Development
Orion's dedication to advancing pharmaceutical R&D is intrinsic to their strategy. With a robust workforce of around 3,600 employees, the company is well-equipped to tackle complex medical challenges through continuous innovation in therapeutic development.
Contact Information
For inquiries regarding the collaboration or Orion's broader initiatives, interested parties can reach out to Antti Haapalinna, Vice President of External Science & Partnering R&D, at +358 10 426 7670.
Frequently Asked Questions
What is the primary focus of the collaboration between Orion and Abilita?
The collaboration focuses on developing innovative antibody therapeutics targeting oncology and pain management.
What technology will Orion utilize in this partnership with Abilita?
Orion will utilize Abilita's Enabled Membrane Protein (EMP™) technology to discover novel antibody therapeutics.
How many antibodies can Orion develop through this collaboration?
Orion is set to develop up to three novel antibodies as part of the agreement.
What benefits will Abilita receive from this collaboration?
Abilita will receive initial payments, milestone rewards, and a share of royalties from the successful commercialization of the antibody programs.
What areas does Orion primarily focus on in its pharmaceutical development?
Orion primarily focuses on oncology and pain management in its pharmaceutical research and development efforts.
